∙ Full-diversity human heavy chain and kappa light chain
∙ Variable regions comprising >99% of commonly
expressed human sequences
∙ Use of only functional variable heavy and kappa light
chain regions, without pseudogenes or duplicates
Methods
• Two cohorts: Atlas™ Full Human Diversity
Mice (FHD/FDk) and wild type B6;129 mice
• Immunogen: CD22
• Adjuvant: RIBI
• Immunization site: Footpad
• 6-week protocol: Twice weekly
Atlas™ Full Human Diversity Mouse for Monoclonal Antibody Discovery
Comparable Anti-CD22 Titers of Atlas™ Full Human Diversity Mice vs. WT Mice
Day 35 Serum Titers EC50 Comparison Soluble CD22
CD22 Single B Cell Campaign
FDH/FDk WT (B6;129)
1
2
3
4
5
6
Log
10
(EC50)
nd
10
3
10
4
10
5
10
6
10
7
0
1
2
3
4
5
Serum Dilution
FDH/FDk
WT
OD
450
nm
m414
m415
m417
m420
m421
m434
m274
m333
m433
m448
IgG+
B
Cells
5670
2836
643
461
FDH/FDk
WT
84% of Hits
63% of Hits
541
291
CD22+
Hits
Unique
CD22+
Hits
0 1000 2000 3000 4000 5000 6000
Screening Progression Per 20,000+ Cells
